Envista Holdings Co. (NYSE:NVST – Get Free Report) has been assigned a consensus rating of “Hold” from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.59.
Several equities research analysts recently weighed in on the company. Bank of America decreased their price objective on Envista from $22.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Stifel Nicolaus lowered their price target on shares of Envista from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, July 30th. JPMorgan Chase & Co. downgraded shares of Envista from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Robert W. Baird lowered their target price on shares of Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Finally, Piper Sandler cut their price target on Envista from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, July 30th.
Get Our Latest Stock Report on NVST
Insider Activity at Envista
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after buying an additional 2,940 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Envista by 538.0% in the 4th quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock valued at $77,000 after purchasing an additional 2,706 shares in the last quarter. Innealta Capital LLC bought a new position in shares of Envista during the 2nd quarter valued at $78,000. Summit Securities Group LLC purchased a new position in Envista in the 2nd quarter worth $85,000. Finally, Signaturefd LLC lifted its stake in Envista by 85.9% in the second quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock worth $89,000 after purchasing an additional 2,470 shares during the last quarter.
Envista Stock Performance
Shares of NVST stock opened at $18.64 on Friday. Envista has a 52 week low of $15.15 and a 52 week high of $28.67. The firm’s 50-day simple moving average is $17.52 and its two-hundred day simple moving average is $18.44. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -25.94 and a beta of 1.31. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.90 and a current ratio of 2.22.
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.16). Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The firm had revenue of $633.10 million during the quarter, compared to analysts’ expectations of $646.88 million. During the same quarter in the previous year, the company posted $0.43 EPS. Envista’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, equities analysts forecast that Envista will post 0.69 earnings per share for the current year.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- How to Effectively Use the MarketBeat Ratings Screener
- Should You Invest in Treasury Bills?
- Which Wall Street Analysts are the Most Accurate?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.